"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 6 | 3 | 9 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 6 | 4 | 10 |
| 2008 | 9 | 1 | 10 |
| 2009 | 4 | 1 | 5 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 10 | 21 |
| 2012 | 4 | 5 | 9 |
| 2013 | 11 | 12 | 23 |
| 2014 | 10 | 5 | 15 |
| 2015 | 8 | 7 | 15 |
| 2016 | 19 | 6 | 25 |
| 2017 | 9 | 14 | 23 |
| 2018 | 16 | 9 | 25 |
| 2019 | 5 | 9 | 14 |
| 2020 | 6 | 10 | 16 |
| 2021 | 6 | 7 | 13 |
| 2022 | 1 | 11 | 12 |
| 2023 | 2 | 13 | 15 |
| 2024 | 8 | 11 | 19 |
| 2025 | 7 | 13 | 20 |
| 2026 | 9 | 5 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 05 14; 147(20):2298-2314.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
N-acetylaspartate from fat cells regulates postprandial body temperature. Nat Metab. 2025 Aug; 7(8):1524-1535.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 12; 152(6):1470-1492.
-
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023 11 01; 41(31):4842-4848.
-
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. Cancer Chemother Pharmacol. 2023 02; 91(2):191-201.
-
Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. Circ Cardiovasc Imaging. 2022 11; 15(11):e013676.
-
TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions. Neuro Oncol. 2022 06 01; 24(6):1008-1009.